Senzime Reaffirms Its Target of Reaching Positive Cash Flow Within Q4 2026

Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability

Senzime Secures Additional Major US Hospital Network Contract, Expanding Adoption of its Next-generation Neuromuscular Monitoring Technology

Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed

Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds

Senzime and Philips Medical Systems Enter Development and Commercialization Partnership

Invitation to Presentations of Senzime's Second Quarter 2026 Report

Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Senzime Strengthens Position in Pediatric Anesthesia by Securing Another Hospital Contract and Highlighting Positive Outcome Data

Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor

From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System

Bulletin From Annual General Meeting in Senzime AB (publ)

Senzime Strengthens U.S. Operations with New Leadership Appointments

Margins Strengthened and Cash Flow Improved Despite a Temporary Dip in The Growth Trajectory. Full-Year Targets Remain on Track

Senzime Wins Expanded Contract Within Leading Southeastern US Hospital System

Notice of Annual General Meeting in Senzime AB (publ)

Invitation to Presentations of Senzime's First Quarter 2026 Report

Senzime Secures Strategic Hospital Orders Within Leading US Integrated Healthcare Delivery Network

Senzime Launches TetraCom Connectivity Platform Enabling Universal Transmission of Anesthesia Data

Senzime Secures Credit Line Facility of 50 MSEK

Senzime Q4 2025: Accelerated Growth and Continued Clear Path to Profitability

Invitation to Presentations of Senzime's Q4 and Year-End Report 2025

Senzime Secures Major Ivy League US Hospital System Contract

Senzime's Next-Generation TetraGraph System Receives Regulatory Approval in Japan

Senzime Unveils the Next Set of Innovations in Neuromuscular Monitoring With the Launch of EMGINE Sirius

Senzime Secures Major TetraGraph Order from Leading UK NHS Hospital System

Senzime to Present at Redeye and BioStock Investor Conferences

Nomination Committee for Senzime Annual General Meeting 2026

Senzime Q3 2025: Strong Growth and Clear Steps Towards Profitability

Invitation to Presentations of Senzime's Third Quarter 2025 Report

Senzime Launches EMGINE, The Next-Generation Software Suite Advancing Neuromuscular Monitoring

Senzime Welcomes New European Pediatric Guidelines Recommending EMG-Based Neuromuscular Monitoring

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

Senzime Welcomes New Japanese Guidelines on Neuromuscular Monitoring

Extensive Clinical and Competitive Evaluation Leads Major California University Hospital System to Standardize on Senzime's TetraGraph System

Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System

New Number of Shares and Votes in Senzime AB (publ)

Senzime's TetraGraph System Receives Regulatory Approval in Mexico

Interim Report April-June 2025: 88% Growth in Local Currency

Senzime's Licensee Fukuda Denshi Expands Market Reach with Regulatory Approvals in the US and UK